MedTrace Logo

Myoinositol Treatment and Asprosin Levels in PCOS

NCT05951309 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-07-19

No results posted yet for this study

Summary

Policystic ovary syndrome is the most common endocrinopthy during reproductive period. One of the factors implicated in the pathogenesis is insulin resistance. Asprosin, which is secreted from white adipose tissue is a new candidate for insulin resistance. Myoinositol is known to reduce insulin resistance in PCOS patients. The effect of myoinsitol on serum asprosin levels is unknown yet. This study aimed to evaluate the effect of myoinositol on serum asprosin levels in PCOS patients.

Conditions

Interventions

DRUG

inofolic combi

The patients in this group were given inofolic combi once a day for 12-16 weeks

DRUG

Glucophage 500Mg Tablet

The patients in this group were given glucophage three times a day for 12-16 weeks

Sponsors & Collaborators

  • Near East University, Turkey

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-09-30
Completion
2023-06-03

Countries

  • Cyprus

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05951309 on ClinicalTrials.gov